NEW YORK, NY--(Marketwired - Dec 16, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Albany Molecular Research Inc. ("Albany Molecular" or the "Company") (NASDAQ: AMRI) securities between August 5, 2014 and November 5, 2014.

For more information, click here: http://zlk.9nl.com/albany-molecular-amri.

The complaint alleges that Albany Molecular misrepresented and/or failed to disclose material adverse facts about the Company's operations, financial performance and prospects.

On November 5, 2014, the Company announced an $8.6 million loss for third quarter 2014, attributing the weak quarter to, among other things, a business interruption at its OsoBio facility.

If you suffered a loss in Albany Molecular you have until January 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/albany-molecular-amri. 

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.